Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 2

2(33.3%)

Phase 4

1(16.7%)

6Total

N/A(3)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06881472Not ApplicableCompleted

The Separate and Combined Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Subjects With and Without Type 1 Diabetes

Role: lead

NCT07373236Not ApplicableCompleted

The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes

Role: lead

NCT05949281Phase 2Active Not Recruiting

Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes

Role: lead

NCT07247734Phase 2Recruiting

The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation

Role: lead

NCT07042165Phase 4Recruiting

Treatment of Bile Acid Diarrhoea With Atorvastatin

Role: lead

NCT05078255Not ApplicableCompleted

The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes

Role: lead

All 6 trials loaded